Comment on: Infliximab, etanercept and adalimumab for the treatment of ankylosing spondylitis: cost-effectiveness evidence and NICE guidance: reply

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Rheumatology

• Publication date

  2008-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/RHEUMATOLOGY/KEN326
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Comment on: Infliximab, etanercept and adalimumab for the treatment of ankylosing spondylitis: cost-effectiveness evidence and NICE guidance.

  2008cited by this paper
• Infliximab, etanercept and adalimumab for the treatment of ankylosing spondylitis: cost-effectiveness evidence and NICE guidance.

  2007cited by this paper
• Comparison of the cost-effectiveness of infliximab in the treatment of ankylosing spondylitis in the United Kingdom based on two different clinical trials

  2007cited by this paper
• Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.

  2007cited by this paper

• Impacto económico de la utilización de los antagonistas del factor de necrosis tumoral en artropatías inflamatorias

  2016cites this paper
• Association of serum interleukin‐17 and interleukin‐23 levels with disease activity in Chinese patients with ankylosing spondylitis

  2012cites this paper
• Etanercept in spondyloarthopathies. Part II: safety and pharmacoeconomic issues.

  2011cites this paper
• Cost-effectiveness of etanercept in patients with severe ankylosing spondylitis in Germany.

  2010cites this paper
• Release and activity of anti-TNFalpha therapeutics from injectable chitosan preparations for local drug delivery.

  2008cites this paper